强生(JNJ.US)/传奇生物(LEGN.US)CAR-T疗法3期取得积极结果

智通财经07-03

智通财经APP获悉，7月3日，强生(JNJ.US)与传奇生物(LEGN.US)共同宣布了3期CARTITUDE-4研究预定第二次中期分析的积极结果，该研究评估了两者联合开发的嵌合抗原受体(CAR)T疗法Carvykti与标准疗法相比，用于治疗复发性或经过1线治疗对来那度胺(lenalidomide)耐药的多发性骨髓瘤(MM)患者。中期分析显示，与标准疗法相比，接受Carvykti治疗患者的总生存期...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2448146133?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-03 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2448146133","market":"us","top_or_hot":-1,"title":"强生(JNJ.US)/传奇生物(LEGN.US)CAR-T疗法3期取得积极结果","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，7月3日，强生(JNJ.US)与传奇生物(LEGN.US)共同宣布了3期CARTITUDE-4研究预定第二次中期分析的积极结果，该研究评估了两者联合开发的嵌合抗原受体(CAR)T疗法Carvykti与标准疗法相比，用于治疗复发性或经过1线治疗对来那度胺(lenalidomide)耐药的多发性骨髓瘤(MM)患者。中期分析显示，与标准疗法相比，接受Carvykti治疗患者的总生存期...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1144854.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>强生(JNJ.US)/传奇生物(LEGN.US)CAR-T疗法3期取得积极结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n强生(JNJ.US)/传奇生物(LEGN.US)CAR-T疗法3期取得积极结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-03 10:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1144854.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，7月3日，强生(JNJ.US)与传奇生物(LEGN.US)共同宣布了3期CARTITUDE-4研究预定第二次中期分析的积极结果，该研究评估了两者联合开发的嵌合抗原受体(CAR)T疗法Carvykti与标准疗法相比，用于治疗复发性或经过1线治疗对来那度胺(lenalidomide)耐药的多发性骨髓瘤(MM)患者。中期分析显示，与标准疗法相比，接受Carvykti治疗患者的总生存期...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1144854.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0795875169.SGD","symbol_name":"JPMorgan Investment Funds - Global Income A (div) SGD-H","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1144854.html","article_id":"2448146133","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2448146133","pubTimestamp":1719972232,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，7月3日，强生与传奇生物共同宣布了3期CARTITUDE-4研究预定第二次中期分析的积极结果，该研究评估了两者联合开发的嵌合抗原受体T疗法Carvykti与标准疗法相比，用于治疗复发性或经过1线治疗对来那度胺耐药的多发性骨髓瘤患者。Carvykti是获批用于多发性骨髓瘤患者二线或以上治疗的首个B细胞成熟抗原靶向CAR-T疗法。BCMA主要表达于恶性多发性骨髓瘤B细胞、晚期B细胞和浆细胞的表面。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","JNJ":"强生","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LEGN":"传奇生物","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4592":"伊斯兰概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","CAR":"安飞士","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","BK4139":"生物科技","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4559":"巴菲特持仓","BK4588":"碎股","BK4550":"红杉资本持仓","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","BK4568":"美国抗疫概念","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BK4022":"陆运","BK4505":"高瓴资本持仓","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","BK4581":"高盛持仓","BK4504":"桥水持仓","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC"},"translate_title":"Johnson & Johnson (JNJ.US)/Legend Bio (LEGN.US) CAR-T Therapy Phase 3 Achieves Positive Results","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1,"LEGN":1,"JNJ":1},"content_text":"智通财经APP获悉，7月3日，强生(JNJ.US)与传奇生物(LEGN.US)共同宣布了3期CARTITUDE-4研究预定第二次中期分析的积极结果，该研究评估了两者联合开发的嵌合抗原受体(CAR)T疗法Carvykti与标准疗法相比，用于治疗复发性或经过1线治疗对来那度胺(lenalidomide)耐药的多发性骨髓瘤(MM)患者。中期分析显示，与标准疗法相比，接受Carvykti治疗患者的总生存期(OS)有统计学和临床意义上的改善。据悉，详细数据将公布于即将来临的医学会议当中，并递交给全球监管单位。Carvykti是获批用于多发性骨髓瘤患者二线或以上治疗的首个B细胞成熟抗原(BCMA)靶向CAR-T疗法。资料显示，Carvykti是一种靶向BCMA的CAR-T细胞疗法，使用嵌合抗原受体的转基因对患者自身的T细胞进行修饰，以识别和消除表达BCMA的细胞。BCMA主要表达于恶性多发性骨髓瘤B细胞、晚期B细胞和浆细胞的表面。Carvykti的CAR蛋白具有两种靶向BCMA单域抗体，对表达BCMA的细胞具有高亲和力，在与表达BCMA的细胞结合后，CAR可促进T细胞活化、扩增，继而清除靶细胞。该疗法在今年4月获FDA批准，用于治疗复发性或难治性多发性骨髓瘤成年患者，这些患者之前曾至少接受过包括蛋白酶体抑制剂(PI)和免疫调节剂(IMiD)的一线治疗，并对来那度胺耐药。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448146133"}